Applied Therapeutics, Inc. (APLT) Dividend History

Applied Therapeutics, Inc. is a biotechnology company focused on developing treatments for serious, rare, and unmet medical conditions, particularly in the areas of metabolic and neurodegenerative diseases. The company utilizes a novel approach to drug discovery, leveraging its proprietary platform to identify and develop targeted therapies aimed at addressing underlying disease mechanisms.

545 Fifth Avenue, Suite 1400, New York, NY, 10017
Phone: 212-220-9226
Website: https://www.appliedtherapeutics.com

Dividend History

Applied Therapeutics, Inc. currently does not pay dividends

Company News

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics presented positive 12-month and 24-month data from its INSPIRE trial of govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), a rare neuromuscular disease. The data showed significant reductions in blood sorbitol levels and improvements in functional and patient-reported outcomes.

GlobeNewswire Inc.
Applied Therapeutics Reports First Quarter 2025 Financial Results

Applied Therapeutics, a clinical-stage biopharmaceutical company, will present full 12-month clinical data and new topline 18-month and 24-month data from its INSPIRE Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting. The company is also reviewing the development programs for govorestat in Classic Galactosemia and CMT-SORD Deficiency.

GlobeNewswire Inc.
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics announced that it will present full 12-month clinical results from the INSPIRE Phase 3 trial of govorestat (AT-007) in a late-breaking abstract selected for oral presentation at the Peripheral Nerve Society 2025 Annual Meeting. The presentation will also include new topline 18-month and 24-month data prior to the transition to the open-label extension study.

GlobeNewswire Inc.
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

Applied Therapeutics, a clinical-stage biopharmaceutical company, announced key senior appointments and reported its financial results for the fourth quarter and full year 2024. The company is focused on preparing for potential regulatory interactions regarding its lead drug candidate, govorestat, for the treatment of Classic Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency.

GlobeNewswire Inc.
APLT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT

A class action lawsuit has been filed against Applied Therapeutics, Inc. (APLT) for allegedly making false and/or misleading statements during the class period from January 3, 2024 to December 2, 2024. The lawsuit claims that the company did not adhere to trial protocol and good clinical practices, which created a risk that the trial data would be rejected by the FDA.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 21:19:08 UTC